National Advertising Division Will Refer Beyond Air to Regulatory Authorities for Declining to Participate in Self-Regulatory Process
New York, NY – November 18, 2026 – Following a challenge by Vero Biotech Inc., BBB National Programs’ National Advertising Division will refer Beyond Air, Inc. to the appropriate regulatory authorities.
Vero and Beyond Air are competitors in the market for inhaled nitric oxide (iNO) used to treat neonates with hypoxic respiratory failure associated with pulmonary hypertension.
In a Fast-Track SWIFT challenge, an expedited process designed for single-issue advertising cases, Vero challenged claims that Beyond Air’s LungFit® PH system has no logistical dependency or materially less logistical dependency and burden than Vero’s GENOSYL® Delivery System, including with respect to supplies, consumables, and shipping required for their indicated usage.
Beyond Air informed NAD that it would not participate in the advertising industry’s self-regulatory process. Pursuant to Section 2.1(I)(3) of the NAD/NARB Procedures, NAD will refer the matter to the appropriate regulatory authorities.
All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. Per NAD/NARB Procedures, this release may not be used for promotional purposes.
Vero and Beyond Air are competitors in the market for inhaled nitric oxide (iNO) used to treat neonates with hypoxic respiratory failure associated with pulmonary hypertension.
In a Fast-Track SWIFT challenge, an expedited process designed for single-issue advertising cases, Vero challenged claims that Beyond Air’s LungFit® PH system has no logistical dependency or materially less logistical dependency and burden than Vero’s GENOSYL® Delivery System, including with respect to supplies, consumables, and shipping required for their indicated usage.
Beyond Air informed NAD that it would not participate in the advertising industry’s self-regulatory process. Pursuant to Section 2.1(I)(3) of the NAD/NARB Procedures, NAD will refer the matter to the appropriate regulatory authorities.
All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. Per NAD/NARB Procedures, this release may not be used for promotional purposes.